Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy

Cancer

Volumn 115, Issue 5, 2009, Pages 981-987

  Choueiri, Toni K ^a,b   Xie, Wanling ^a   D'Amico, Anthony V ^a   Ross, Robert W ^a   Hu, Jim C ^a   Pomerantz, Mark ^a   Regan, Meredith M ^a   Taplin, Mary Ellen ^a   Kantoff, Philip W ^a   Sartor, Oliver ^a   Oh, William K ^a  

^a Harvard Medical School ^*

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Androgen deprivation therapy; Hormone sensitive metastatic prostate cancer; Prostate cancer; Prostate specific antigen kinetics; Time to prostate specific antigen nadir

Indexed keywords

ANTIANDROGEN; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL EVALUATION; COHORT ANALYSIS; DATA BASE; DISEASE SEVERITY; FOLLOW UP; HORMONE SENSITIVITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORCHIECTOMY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SURVIVAL TIME;

EID: 61449222946     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24064     Document Type: Article

References (12)

1. Taplin ME. Drug insight: role of the androgen receptor in the development and progression, of prostate cancer. Nat Clin Pract Oncol. 2007;4:236-244.
2. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.
3. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440-447.
4. Zhou P, Chen. MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005;23:6992-6998.
5. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984-3990.
6. Oh WK, Hayes J, Evan C, et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer. 2006;5:61-66.
7. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25:1596-1605.
8. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
9. Petrylak. DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006;98:516-521.
10. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25:3965-3970.
11. Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schroder FH. Is prostate-specific antigen a valid, surrogate endpoint for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol. 2005;23:6139-6148.
12. Oosterlinck W, Mattelaer J, Casselman J, Van Velthoven R, Derde MP, Kaufman L. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients. Acta Urol Belg. 1997:65:63-71.